Luca Rastelli

Luca Rastelli is an accomplished professional with extensive experience in the biotechnology and pharmaceutical industries, currently serving as Chief Scientific Officer at DeepCure since April 2024. Prior to this role, Luca held the position of Chief Scientific Officer at Jubilant Therapeutics Inc. from March 2021 to March 2024 and served as CSO at Kleo Pharmaceuticals Inc. from April 2018 to March 2021. Additionally, Luca was Vice President of Oncology R&D at BioXcel, LLC from May 2015 to March 2018, and held leadership roles in business development and translational strategy at Boston Strategics Corporation. Earlier in the career, Luca worked at Merck Serono as a global project team leader focusing on novel oncology therapeutics, and held significant positions at Sopherion Therapeutics and Curagen. Luca earned a Ph.D. in Molecular Biology from the University of Geneva between 1992 and 1994.